ADAP vs. ACB, ATXS, CMPX, DRUG, MNPR, NVCT, LFCR, YMAB, SLRN, and IMMP
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Aurora Cannabis (ACB), Astria Therapeutics (ATXS), Compass Therapeutics (CMPX), Bright Minds Biosciences (DRUG), Monopar Therapeutics (MNPR), Nuvectis Pharma (NVCT), Lifecore Biomedical (LFCR), Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry.
Adaptimmune Therapeutics vs.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Aurora Cannabis has a net margin of 0.42% compared to Adaptimmune Therapeutics' net margin of -25.43%. Aurora Cannabis' return on equity of 0.59% beat Adaptimmune Therapeutics' return on equity.
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 1 mentions for Adaptimmune Therapeutics and 0 mentions for Aurora Cannabis. Adaptimmune Therapeutics' average media sentiment score of 1.01 beat Aurora Cannabis' score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media.
Aurora Cannabis received 58 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. However, 63.42% of users gave Adaptimmune Therapeutics an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote.
Adaptimmune Therapeutics presently has a consensus target price of $1.83, indicating a potential upside of 586.42%. Given Adaptimmune Therapeutics' higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Aurora Cannabis.
Aurora Cannabis has higher revenue and earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Summary
Aurora Cannabis beats Adaptimmune Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADAP) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy ADAP Stock Free ADAP Stock Alerts